This paper examines the viability of entering the medical supplies market in Mozambique, with a focus on HIV/AIDS antiretroviral therapy (ART) products. It evaluates Mozambique's economic environment, the cost structure of ART delivery, demand drivers such as international funding initiatives, and competitor pricing behavior — particularly that of GlaxoSmithKline. The paper further analyzes revenue sources through palliative care, operating and start-up costs within the National Health System, and profitability considerations tied to drug patent protections under TRIPS. It concludes with an assessment of financial gains, broader economic benefits, and social costs related to rural populations and healthcare adoption in Mozambique.
Mozambique is one of the more economically progressive nations on the African continent. A reformation of the economy has been underway through the elimination of subsidies and quantitative restrictions on imports, the reduction and simplification of import tariffs, and the liberalization of crop marketing. The nation is endowed with natural resources that support the development of agriculture, tourism, energy, and fisheries industries. Its ideal trading location means that large exports in these sectors increase the amount of foreign exchange brought into the country. The area's proximity to South Africa has also resulted in important cross-border projects that support higher levels of economic growth.
According to available data, the GDP of Mozambique in 2002 was US$3.9 billion. Of this total, agriculture accounted for 23.3%, industries for 31%, and services for 45.7%. Foreign direct investment (FDI) into the country reached US$479.9 million for the year 2001 (Mozambique Overview).
As AIDS continues to be one of the major diseases affecting Mozambique, antiretroviral therapy (ART) lowers the occurrence of opportunistic infections and allows HIV-positive individuals to survive longer. However, the high cost and complexity of administering antiretroviral drugs (ARVs) have seriously restricted their use in resource-constrained environments, where the majority of HIV-infected persons reside. Strong patient adherence to ART is vital for successful treatment. In many settings where resources are scarce and HIV prevalence is high, trained medical personnel, laboratory services, and drug management systems are critically limited (About Our Work: Antiretroviral Therapy).
Despite the prohibitive costs of ART, its use is increasing, and the therapy is likely to become more widely available due to several encouraging developments. First, funding for ART programs is available through the Global Fund to Fight AIDS, TB and Malaria and the World Bank's Multi-Country AIDS Program (MAP). Second, the WHO has issued guidelines for scaling up ART delivery in resource-constrained settings. Third, the Presidential Emergency Plan for AIDS Relief (PEPFAR), launched in January 2003, set as one of its key objectives the treatment of two million HIV-infected people with ART in 15 of the world's most affected nations by 2008 (GAP: Antiretroviral Therapy).
Despite urgent need and severe constraints on Africa's health budgets, GlaxoSmithKline's (GSK) drug lamivudine — used in the treatment of HIV/AIDS — is on average one-fifth more expensive in Africa than in ten surveyed high-income nations. The cost of lamivudine in Mozambique reaches as high as US$810. In recognition of the need to address the cost of HIV/AIDS medicines, GSK participates in the joint industry/United Nations Accelerating Access Initiative, which offers medications at considerably reduced prices. However, significant affordability challenges remain for the populations most affected (Dare to Lead: public health and company wealth).
"Palliative care revenue and BEE market entry"
"NHS structure, patent protection, and profit estimates"
"Combivir profits, healthcare gains, rural social change"
You’re 38% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.